AALL1732: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494 NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL Mixed Phenotype Acute Leukemia and Disseminated B-LLy

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Newly Diagnosed High-risk B-all; Risk-adapted Post-induction Therapy For High-risk B-all, Mixed Phenotype Acute Leukemia, And Disseminated B-lly
  • Age: Between 1 Year(s) - 25 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    In order to participate in this study, the following criteria must be met: White blood cell count (WBC) criteria for patients with B-ALL (within 7 days prior to the start of protocol-directed systemic therapy): 1) Age 1-9.99 years: WBC >= 50,000/uL

You may not be eligible for this study if the following are true:

  • You will not be able to participate in this study if: 1) Patients with Down syndrome are not eligible (patients with Down syndrome and B-ALL are eligible for AALL1731, regardless of NCI risk group). 2) Patients with acute undifferentiated leukemia (


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.